OM on Nasdaq
Outset Medical, Inc.
American electromedical and electrotherapeutic apparatus company.
$4.07 up 0.23 (5.99%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 18, 2026.
Overview
Compare with ViewRay, BIOLIFE SOLUTIONS INC or VASO Corp, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
39.1%Gross margin4
-55.8%Operating margin4
-68.3%Net margin4
5.1%Revenue growth, 20254
-64.3%Return on equity4
0.76×Debt to equity4
-$47.1MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Consumables Product brought in 45% of the revenue Outset Medical, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Consumables Product | $42.2M | $51.1M | $54.1M |
| Service and Other Revenue | $26.8M | $32.7M | $34.7M |
| Consoles Product | $61.3M | $29.8M | $30.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue61¢$72.7M
- Research and development18¢$21.2M
- Other costs9¢$10.8M
- Interest12¢$14.0M
- Income tax1¢$718.0K
Out of $119.5M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $119.5M | $113.7M | $130.4M |
| Cost of revenue | $72.7M | $75.1M | $101.4M |
| Gross profit | $46.8M | $38.6M | $29.0M |
| Research and development | $21.2M | $38.4M | $57.3M |
| Sales and marketing | $54.4M | $70.0M | $96.2M |
| General and administrative | $37.9M | $43.5M | $45.2M |
| Total operating expenses | $113.5M | $151.9M | $198.8M |
| Loss from operations | -$66.7M | -$113.4M | -$169.8M |
| Interest income and other income, net | $7.4M | $9.8M | $10.2M |
| Interest expense | -$14.0M | -$23.9M | -$12.7M |
| Loss on extinguishment of term loan | -$7.7M | $0 | $0 |
| Loss before provision for income taxes | -$80.9M | -$127.5M | -$172.3M |
| Provision for income taxes | $718.0K | $491.0K | $523.0K |
| Net loss | -$81.7M | -$128.0M | -$172.8M |
| Net loss per share, basic | -$5.37 | -$36.96 | -$52.28 |
| Net loss per share, diluted | -$5.37 | -$36.96 | -$52.28 |
| Shares used in computing net loss per share, basic | 15.2K shares | 3.5K shares | 3.3K shares |
| Shares used in computing net loss per share, diluted | 15.2K shares | 3.5K shares | 3.3K shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $35.0M | $124.0M | ||
| Short-term investments | $133.9M | $34.7M | ||
| Accounts receivable, net | $28.3M | $35.6M | ||
| Inventories | $47.6M | $59.4M | ||
| Prepaid expenses and other current assets | $6.0M | $4.5M | ||
| Total current assets | $250.9M | $258.2M | ||
| Restricted cash | $3.8M | $3.3M | ||
| Property and equipment, net | $4.7M | $8.1M | ||
| Operating lease right-of-use assets | $4.8M | $3.9M | ||
| Other assets | $317.0K | $2.2M | ||
| Total assets | $264.5M | $275.8M | ||
| Accounts payable | $554.0K | $3.9M | ||
| Accrued compensation and related benefits | $10.7M | $16.8M | ||
| Accrued expenses and other current liabilities | $9.4M | $8.2M | ||
| Accrued warranty liability | $1.4M | $1.9M | $3.7M | |
| Deferred revenue, current | $13.8M | $12.8M | ||
| Operating lease liabilities, current | $1.7M | $1.8M | ||
| Total current liabilities | $37.6M | $45.4M | ||
| Accrued interest | $0 | $2.7M | ||
| Deferred revenue | $406.0K | $844.0K | ||
| Operating lease liabilities | $3.3M | $2.7M | ||
| Term loans | $96.2M | $197.4M | ||
| Total liabilities | $137.5M | $249.0M | ||
| Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2025 and 2024; 18,169 and 3,530 shares issued and outstanding as of December 31, 2025 and December 31, 2024 respectively | $18.0K | $4.0K | ||
| Additional paid-in capital | $1.3B | $1.1B | ||
| Accumulated other comprehensive income | $172.0K | $42.0K | ||
| Accumulated deficit | -$1.2B | -$1.1B | ||
| Total stockholders' equity | $127.0M | $26.8M | $122.9M | $246.0M |
| Total liabilities and stockholders' equity | $264.5M | $275.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 18.2M shares | 3.5M shares | ||
| Common stock, shares outstanding | 18.2M shares | 3.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $35.0M | $124.0M | ||
| Short-term investments | $133.9M | $34.7M | ||
| Accounts receivable, net | $28.3M | $35.6M | ||
| Inventories | $47.6M | $59.4M | ||
| Prepaid expenses and other current assets | $6.0M | $4.5M | ||
| Total current assets | $250.9M | $258.2M | ||
| Restricted cash | $3.8M | $3.3M | ||
| Property and equipment, net | $4.7M | $8.1M | ||
| Operating lease right-of-use assets | $4.8M | $3.9M | ||
| Other assets | $317.0K | $2.2M | ||
| Total assets | $264.5M | $275.8M | ||
| Accounts payable | $554.0K | $3.9M | ||
| Accrued compensation and related benefits | $10.7M | $16.8M | ||
| Accrued expenses and other current liabilities | $9.4M | $8.2M | ||
| Accrued warranty liability | $1.4M | $1.9M | $3.7M | |
| Deferred revenue, current | $13.8M | $12.8M | ||
| Operating lease liabilities, current | $1.7M | $1.8M | ||
| Total current liabilities | $37.6M | $45.4M | ||
| Accrued interest | $0 | $2.7M | ||
| Deferred revenue | $406.0K | $844.0K | ||
| Operating lease liabilities | $3.3M | $2.7M | ||
| Term loans | $96.2M | $197.4M | ||
| Total liabilities | $137.5M | $249.0M | ||
| Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2025 and 2024; 18,169 and 3,530 shares issued and outstanding as of December 31, 2025 and December 31, 2024 respectively | $18.0K | $4.0K | ||
| Additional paid-in capital | $1.3B | $1.1B | ||
| Accumulated other comprehensive income | $172.0K | $42.0K | ||
| Accumulated deficit | -$1.2B | -$1.1B | ||
| Total stockholders' equity | $127.0M | $26.8M | $122.9M | $246.0M |
| Total liabilities and stockholders' equity | $264.5M | $275.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 18.2M shares | 3.5M shares | ||
| Common stock, shares outstanding | 18.2M shares | 3.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$81.7M | -$128.0M | -$172.8M |
| Stock-based compensation expense | $15.6M | $29.4M | $38.6M |
| Depreciation and amortization | $4.3M | $5.7M | $5.8M |
| Non-cash lease expense | $1.6M | $1.4M | $1.3M |
| Non-cash interest expense | $2.8M | $2.6M | $1.8M |
| Amortization of premium on investments, net | -$2.3M | -$4.7M | -$6.4M |
| Change in provision for inventories | -$124.0K | $561.0K | $733.0K |
| Change in provision for credit losses | $3.5M | $2.4M | $184.0K |
| Loss on disposal of property and equipment | $5.0K | $53.0K | $106.0K |
| Loss on extinguishment of term loan | $7.7M | $0 | $0 |
| Accounts receivable | $3.8M | -$5.0M | -$5.1M |
| Inventories | $11.8M | -$10.9M | $1.6M |
| Prepaid expenses and other assets | -$940.0K | $784.0K | $739.0K |
| Accounts payable | -$3.3M | -$1.9M | $5.3M |
| Accrued compensation and related benefits | -$6.1M | -$1.9M | -$2.5M |
| Accrued expenses and other current liabilities | $1.5M | -$5.2M | -$2.6M |
| Accrued warranty liability | -$564.0K | -$1.8M | $91.0K |
| Deferred revenue | $604.0K | $1.8M | $3.0M |
| Operating lease liabilities | -$1.9M | -$1.6M | -$1.3M |
| Accrued interest | -$2.7M | $0 | $0 |
| Net cash used in operating activities | -$46.3M | -$116.3M | -$131.4M |
| Purchases of property and equipment | -$798.0K | -$912.0K | -$3.4M |
| Purchases of investment securities | -$222.0M | -$156.6M | -$172.3M |
| Sales and maturities of investment securities | $125.1M | $261.4M | $258.8M |
| Net cash (used in) provided by investing activities | -$97.7M | $103.9M | $83.0M |
| Proceeds from stock option exercises and ESPP purchases | $639.0K | $2.3M | $10.4M |
| Proceeds from issuance of term loans, net of issuance costs | $98.3M | $66.5M | $33.2M |
| Repayment of term loan and extinguishment costs | -$205.0M | $0 | $0 |
| Proceeds from issuance of Series A convertible preferred stock, net of issuance costs | $161.5M | $0 | $0 |
| Payment of deferred financing costs | $0 | -$938.0K | $0 |
| Net cash provided by financing activities | $55.5M | $67.9M | $43.7M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$88.5M | $55.5M | -$4.7M |
| Cash paid for income taxes | $447.0K | $593.0K | $491.0K |
| Cash paid for interest | $15.6M | $20.7M | $10.8M |
| Cash paid for amounts included in the measurement of operating lease liabilities | $1.9M | $1.6M | $1.3M |
| Transfer of inventories to property and equipment | $109.0K | $148.0K | $119.0K |
| Right-of-use assets obtained in exchange for operating lease liabilities | $2.4M | $0 | $528.0K |
| Fair value of common stock warrant | $4.4M | $0 | $0 |
| Issuance costs included in accrued expenses | $0 | $266.0K | $0 |
| Capital expenditures included in accounts payable and accrued expenses | $0 | $31.0K | $159.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Outset Medical, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerLeslie Trigg Sep 14, 2020 to now12
- ChairLeslie Trigg Mar 2, 2022 to now13
- PresidentLeslie Trigg Sep 14, 2020 to Jun 2, 202112
- Chief financial officerRenee Gaeta Jun 3, 2025 to now14
- Chief financial officerNabeel Ahmed Jul 19, 2021 to Jun 3, 202515
- Chief financial officerRebecca Chambers Sep 14, 2020 to Jun 25, 202116
- Chief operating officerMartin Vazquez Sep 14, 2020 to Mar 2, 202317
Board members and other officers (22)
- EVP, CommercialDerick A. Elliott Apr 8, 2026 to now18
- VP ManufacturingMarc Nash Jul 24, 2023 to now19
- Chief Technology OfficerJean-Olivier Racine Jun 23, 2021 to May 10, 202420
- VP FinanceNabeel Ahmed Aug 11, 2021 to Aug 11, 202121
- Chief People OfficerStacey L. Porter Oct 21, 2021 to Jan 17, 202422
- Board memberKaren Prange Jan 12, 2026 to now23
- Board memberKevin C. Oboyle May 14, 2025 to now24
- Board memberBrent D. Lang Mar 13, 2024 to now25
- Board memberDale E. Jones Apr 25, 2022 to May 29, 202426
- Board memberKaren Drexler Jan 12, 2021 to now27
- Board memberAndrea L. Saia Mar 24, 2021 to now28
- Board memberCatherine M. Szyman May 24, 2021 to May 31, 202329
- Board memberAli Osman Sep 14, 2020 to Sep 14, 202030
- Board memberD. Keith Grossman Sep 14, 2020 to now31
- Board memberGp L.p. Wpx Sep 14, 2020 to Jan 7, 202132
- Board memberJames F. Hinrichs Sep 14, 2020 to May 29, 202433
- Board memberLeslie Trigg Sep 14, 2020 to Feb 3, 202212
- Board memberPatrick T. Hackett Sep 14, 2020 to now34
- Board memberPincus X. L.p. Warburg Sep 14, 2020 to Jan 7, 202132
- Board memberThomas J. Carella Sep 14, 2020 to Sep 14, 202035
- Board memberX. Finance L.p. Wp Sep 14, 2020 to Jan 7, 202132
- General counselJohn L. Brottem Sep 14, 2020 to now36
Former names
- Home Dialysis Plus, Ltd.Feb 26, 2010 to Feb 25, 20113
Timeline
- Sep 14, 2020New chief executive Leslie Trigg becomes CEO12
Filings
575 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 290 insider forms, 67 large holders, 1 private raises, 145 other. The latest 20:
- Oct 6, 2026SCHEDULE 13G/A EDGAR
- Oct 5, 20264 EDGAR
- Aug 28, 20268-K EDGAR
- Aug 18, 20264 PRIMARY DOCUMENT EDGAR
- Aug 18, 20264 PRIMARY DOCUMENT EDGAR
- Aug 18, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 29, 2026SCHEDULE 13G/A EDGAR
- Jun 29, 20264 PRIMARY DOCUMENT EDGAR
- Jun 29, 20264 PRIMARY DOCUMENT EDGAR
- Jun 29, 20264 PRIMARY DOCUMENT EDGAR
- Jun 17, 20268-K EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
- Jun 5, 20264 PRIMARY DOCUMENT EDGAR
The 575 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 67 such filings since October 2021, the latest 10:
- Oct 6, 2026SCHEDULE 13G/A
- Aug 12, 2026SCHEDULE 13G
- Aug 12, 2026SCHEDULE 13G/A
- Jul 29, 2026SCHEDULE 13G/A
- May 18, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 12, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Jan 3, 2025Raised $3.9 million in a private offering of equity Form D: 13 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 92. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 2,742,887 | $11.8M | 0.0% | +1,214 |
| BML Capital Management, LLC | 2,519,701 | $10.9M | 6.2% | +617,500 |
| Aqr Capital Management LLC | 998,961 | $4.3M | 0.0% | +190,676 |
| Perceptive Advisors LLC | 833,333 | $3.6M | 0.1% | No change |
| Vanguard Capital Management LLC | 780,134 | $3.4M | 0.0% | +16,312 |
| Assenagon Asset Management S.A. | 678,876 | $2.9M | 0.0% | +174,783 |
| Bank Of America Corp /de/ | 665,847 | $2.9M | 0.0% | −283,550 |
| PFM Health Sciences, LP | 582,122 | $2.5M | 0.2% | −12,508 |
| Ensign Peak Advisors, Inc | 434,341 | $1.9M | 0.0% | −92,244 |
| BlackRock, Inc. | 418,211 | $1.8M | 0.0% | −845,008 |
| Peapod Lane Capital LLC | 331,951 | $1.4M | 1.0% | New |
| Marshall Wace, Llp | 211,993 | $915.8K | 0.0% | New |
| Geode Capital Management, LLC | 204,652 | $884.5K | 0.0% | −216,721 |
| Stratos Wealth Partners, LTD. | 200,546 | $866.4K | 0.0% | No change |
| UBS Group AG | 190,289 | $822.0K | 0.0% | −62,210 |
| Morgan Stanley | 181,983 | $786.2K | 0.0% | +12,540 |
| Millennium Management LLC | 181,794 | $785.4K | 0.0% | New |
| Goldman Sachs Group Inc | 173,460 | $749.3K | 0.0% | +80,100 |
| Jane Street Group, LLC | 139,197 | $601.3K | 0.0% | +74,387 |
| XTX Topco Ltd | 124,690 | $538.7K | 0.0% | −17,760 |
| Catalio Capital Management, LP | 118,279 | $511.0K | 0.1% | No change |
| Vanguard Fiduciary Trust Co | 114,912 | $496.4K | 0.0% | +3,273 |
| GMT Capital Corp | 98,108 | $423.8K | 0.0% | +55,687 |
| Dimensional Fund Advisors LP | 90,698 | $391.8K | 0.0% | −22,667 |
| Pura Vida Investments, LLC | 83,333 | $360.0K | 1.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceOM quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARLeslie Trigg, Chair
- 14SEC EDGARRenee Gaeta, Chief financial officer
- 15
- 16
- 17
- 18SEC EDGARDerick A. Elliott, EVP, Commercial
- 19SEC EDGARMarc Nash, VP Manufacturing
- 20
- 21SEC EDGARNabeel Ahmed, VP Finance
- 22
- 23SEC EDGARKaren Prange, Board member
- 24SEC EDGARKevin C. Oboyle, Board member
- 25SEC EDGARBrent D. Lang, Board member
- 26SEC EDGARDale E. Jones, Board member
- 27SEC EDGARKaren Drexler, Board member
- 28SEC EDGARAndrea L. Saia, Board member
- 29SEC EDGARCatherine M. Szyman, Board member
- 30SEC EDGARAli Osman, Board member
- 31SEC EDGARD. Keith Grossman, Board member
- 32SEC EDGARGp L.p. Wpx, Board member
- 33SEC EDGARJames F. Hinrichs, Board member
- 34SEC EDGARPatrick T. Hackett, Board member
- 35SEC EDGARThomas J. Carella, Board member
- 36SEC EDGARJohn L. Brottem, General counsel